health $wellness blog

Kozhikode: In a disturbing case of alleged medical negligence reported in the city, a 60-year-old heart patient lost his life at the hands of an unqualified medical practitioner, who had only completed the 12th grade and had been struggling to pass the second year of his MBBS course since 2011. Despite this, he worked as a Resident Medical Officer (RMO) at TMH Hospital in Kottakadavu, Kozhikode. After gathering evidence that the medical practitioner was a quack who enrolled in a hospital but still failed to complete his medical degree, the Kerala police arrested him under relevant sections of BNS and TMH Hospital dismissed him after acknowledging a lapse in verifying his qualifications. It was found that the fake doctor was working illegally as an RMO in EDs of various hospitals for years even though he was enrolled in KMCT Hospital to complete his medical studies.  Also read- Rajasthan Administrative officer dies after botched hysterectomy at Jodhpur Hospital, family alleges ...

New Delhi:  Serum Institute of India has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical trial of dengue monoclonal antibody in children ≥ 5 years and adults with dengue. This came after Serum Institute of India presented the proposal to conduct a Phase III clinical trial titled “A Phase III, double-blind, randomized, placebo-controlled, multicentric study of dengue monoclonal antibody in children ≥ 5 years and adults with dengue” via protocol number: Dengue-mAb-03version 1.0, dated 04 Jul 2024 along with the results of the Phase II study. The Serum Institute of India (SII) is developing a dengue monoclonal antibody drug called Dengushield, which is an antiviral and orphan drug. Dengue monoclonal antibody is an engineered humanised monoclonal antibody that binds to a non-immunodominant epitope on domain III of the envelope protein (EDIII) and has shown potent, speci...

Researchers have developed a laser-based device that can be placed on the head to non-invasively monitor changes in brain blood flow and volume. The new device could one day help save lives by offering a direct and simple way to assess stroke risk based on physiological markers rather than indirect markers like lifestyle factors. Strokes occur when blood flow to the brain is blocked or reduced, causing debilitating brain cell damage. With about 15 million people worldwide affected by strokes each year, it is the second leading cause of death and a leading cause of long-term disability. “The lack of a cost-effective and scalable stroke risk assessment system complicates long-term stroke prevention because a physician can’t tell whether a patient’s risk is stable or worsening,” said research team member Simon Mahler, a postdoctoral scholar in Changhuei Yang’s laboratory at the California Institute of Technology. “This new method could help catch early signs of increased stroke risk, w...

New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a Phase I clinical trial of the Recombinant Human Follicle Stimulating Hormone 300 IU Solution for Injection. However, this approval is subject to the condition that the firm should have tied up with an IVF center in case of an emergency. This came after the firm presented the protocol to conduct a Phase I clinical study of Recombinant Human Follicle Stimulating Hormone 300 IU Solution for Injection titled " An open label, Phase-I, balanced, randomized, two-treatment, two-period, two-sequence, single subcutaneous dose administration, crossover, bioequivalence study of r-h-FSH (recombinant human follicle stimulating hormone injection), solution for injection of Intas Pharmaceuticals Limited, India with Gonal-f, recombinant human follicle stimulating hormone (r-hFSH) follitropin alfa, solution for injection ...

New Delhi- Through a notice, the Indian Council of Medical Research (ICMR) has called for concept proposals for the Centre for Advanced Research (CAR), under the Extramural Research Program. The Last Date for concept proposal is November 21, 2024. Under its Extramural Research Programme, the Indian Council of Medical Research (ICMR) funds the Centre for Advanced Research (CAR) to promote advanced research by experienced research teams.   What the CAR is expected to do: Conducting decisive research that helps in solving an important healthcare problem by a research team. It can have single or multiple linked research projects with clear deliverables. It encourages in-depth research, to generate new knowledge and solutions for health problems in multiple aspects of causation, progression, management and prevention. Priority diseases or conditions: Research teams planning to undertake studies in finding solutions for prevention, screening, diagnosis, treatment or rehabilita...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major GlaxoSmithKline's protocol amendment proposal for the clinical trial titled "A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants with Relapsed or Refractory Multiple Myeloma (DREAMM-14)." This came after GlaxoSmithKline Pharmaceuticals presented protocol amendment 03 dated 25 June 2024 protocol no. 209628. Belantamab mafodotin is a monoclonal antibody conjugated with a cytotoxic agent for the treatment of relapsed and refractory multiple myeloma. Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug conjugate binds to ...

New Delhi:  Welcoming the updated guidelines detailing the functions and responsibilities of the zonal, sub-zonal, and port offices issued by the Central Drugs Standard Control Organization (CDSCO), the Indian Rubber Gloves Manufacturers Association (IRGMA) has urged the government to take stringent measures to implement the order effectively to stop the import of substandard gloves in the country. The CDSCO issued the new Guidance Document for Functions and Responsibilities of Zonal, Sub-zonal, and Port offices on September 12. The guidelines were last released in 2011, and the recent changes include the introduction of new rules and regulations and the online system through the SUGAM portal, which necessitated the revised order in line with the procedures followed in CDSCO offices. Guidance documents for Zonal, Sub zonal and Port offices were prepared in 2011 and implemented since then. It sets out the nature of work that Zonal, sub-zoneal, and port offices generally carry ...